# Fate Therapeutics

iPSC-NK platform — standard batches from a single line.

Source: https://en.bioecon.ru/companies/fate-therapeutics/
Updated: 2026-06-24

- Country: United States

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | $205.1 million in cash, cash equivalents, and investments as of December 31, 2025 | https://last10k.com/sec-filings/fate/0001193125-26-073699.htm, https://www.metatrader.com/en/symbols/nasdaq/fate/documents/234740-annual-report-fy2025 |
| Capacity | 40,000+ square foot GMP manufacturing facility designed to support all phases of clinical development and initial commercialization | https://ir.fatetherapeutics.com/node/13906/html, https://stocklight.com/stocks/us/nasdaq-fate/fate-therapeutics/annual-reports/nasdaq-fate-2026-10K-26682010.pdf |
| Certification | Drug manufacturing license issued by the State of California, Department of Health Services, Food and Drug Branch | https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-announces-opening-its-cgmp-manufacturing |
| Regulatory approval | FDA cleared multiple Investigational New Drug (IND) applications; MHRA and EMA authorization for FT819 clinical trials | https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-reports-third-quarter-2025-financial-results, https://last10k.com/sec-filings/fate/0001193125-26-073699.htm |
| Production site | San Diego, California | https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-announces-opening-its-cgmp-manufacturing |
| Headcount | 161 full-time employees as of December 31, 2025 | https://www.metatrader.com/en/symbols/nasdaq/fate/documents/234740-annual-report-fy2025 |
| Revenue | $6.646 million for fiscal year 2025 | https://www.metatrader.com/en/symbols/nasdaq/fate/documents/234740-annual-report-fy2025 |

Independent sources: last10k.com, metatrader.com, stocklight.com

## Technologies

- [NK-cell & CAR-NK therapy](https://en.bioecon.ru/technology/nk-cell-car-nk-therapy/)